Therapy Insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome

Nature Clinical Practice Neurology

Volumn 2, Issue 10, 2006, Pages 557-565

  Riedel, David J ^a   Pardo, Carlos A ^b   McArthur, Justin ^b   Nath, Avindra ^c  

^a UNIVERSITY OF MARYLAND   (United States)

^b Department of Neurology and Pathology ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CIDOFOVIR; CORTICOSTEROID; STEROID; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL PROTOCOL; DEMENTIA; DRUG FEVER; ENCEPHALITIS; FUNGAL MENINGITIS; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOLOGY; INCIDENCE; MONOTHERAPY; MYCOBACTERIOSIS; NAUSEA; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETINITIS; REVIEW; RISK FACTOR; TUBERCULOSIS; VIRUS LOAD; VOMITING;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN DISEASES; HIV INFECTIONS; HUMANS; INFLAMMATION;

EID: 33749032096     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0303     Document Type: Review

References (62)

1. Kaplan JE et al. (2000) Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30 (Suppl 1): S5-S14
2. d'Arminio Monforte A et al. (2004) Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 55: 320-328
3. Sacktor N et al. (2001) HIV-associated neurologic disease incidence changes: Multicenter AIDS cohort study 1990-1998. Neurology 56: 257-260
4. Mocroft A et al. (2003) Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 362: 22-29
5. Robertson J et al. (2006) Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 42: 1639-1646
6. Shelburne SA et al. (2002) Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81: 213-227
7. Shelburne SA et al. (2006) Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 57: 167-170
8. Lederman MM and Valdez H (2000) Immune restoration with antiretroviral therapies: Implications for clinical management. JAMA 284: 223-228
9. Keane NM et al. (2001) An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol 126: 111-116
10. Wang T et al. (2006) Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. FASEB J 20: 1209-1211
11. Shelburne SA et al. (2005) Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19: 399-406
12. Stoll M and Schmidt RE (2004) Immune restoration inflammatory syndromes: apparently paradoxical clinical events after the initiation of HAART. Curr HIV/ AIDS Rep 1: 122-127
13. French MA et al. (2004) Immune restoration disease after antiretroviral therapy. AIDS 18: 1615-1627
14. Price P et al. (2002) Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 16: 2043-2047
15. French MAH et al. (1992) Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 6: 1293-1297
16. Narita M et al. (1998) Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 158: 157-161
17. Kumarasamy N et al. (2004) Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 37: 1574-1576
18. Lawn SD et al. (2005) Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 5: 361-373
19. Crump JA et al. (1998) Miliary tuberculosis with paradoxical worsening of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infect Dis 26: 1008-1009
20. Murray R et al. (2001) Cerebral Mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation of therapy for disseminated Mycobacterium avium infection. Eur J Clin Microbiol Infect Dis 20: 199-201
21. Navas E et al. (2002) Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 162: 97-99
22. Breen RAM et al. (2004) Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 59: 704-707
23. Katrak SM et al. (2000) The clinical, radiological and pathological profile of tuberculous meningitis in patients with and without human immunodeficiency virus infection. J Neurol Sci 181: 118-126
24. Blanche P et al. (1998) HIV combination therapy: Immune restitution causing cryptococcal lymphadenitis dramatically improved by anti- inflammatory therapy. Scand J Infect Dis 30: 615-616
25. Jenny-Avital ER and Abadi M (2002) Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 35: E128-e133
26. Skiest DJ et al. (2005) Cryptococcal immune reconstitution syndrome: report of four cases and review of the literature. J Infect 51: E289-e297
27. Lortholary O et al. (2005) Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 19: 1043-1049
28. Trevenzoli M et al. (2002) Mediastinitis due to cryptococcal infection: a new clinical entity in the HAART era. J Infect 45: 173-179
29. Woods ML Jr et al. (1998) HIV combination therapy: Partial immune restitution unmasking latent cryptococcal infection. AIDS 12: 1491-1494
30. Boelaert JR et al. (2004) Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy. AIDS 18: 1223-1224
31. King MD et al. (2002) Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: An immune reconstitution syndrome after initiation of highly active antiretroviral therapy. Int J STD AIDS 13: 724-726
32. York J et al. (2005) Raised intracranial pressure complicating cryptococcal meningitis: Immune reconstitution inflammatory syndrome or recurrent cryptococcal disease? J Infect 51: 165-171
33. Shelburne SA III et al. (2005) The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 40: 1049-1052
34. Lawn SD et al. (2005) Cryptococcal immune reconstitution disease: A major cause of early mortality in a South African antiretroviral programme. AIDS 19: 2050-2052
35. Breton G et al. (2002) Paradoxical intracranial cryptococcoma in a human immunodeficiency virus-infected man being treated with combination antiretroviral therapy. Am J Med 113: 155-157
36. Cattelan AM et al. (2004) Multiple cerebral cryptococcomas associated with immune reconstitution in HIV-1 infection. AIDS 18: 349-351
37. Venkataramana A et al. (2006) Immune reconstitution inflammatory syndrome in the CNS of HIV infected patients. Neurology 67: 383-388
38. Cinque P et al. (2001) The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 7: 358-363
39. Safdar A et al. (2002) Fatal immune restoration disease in human immunodeficiency virus type-1 infected patients with progressive multifocal leukoencephalopathy: Impact of antiretroviral therapy- associated immune reconstitution. Clin Infect Dis 35: 1250-1257
40. Vendrely A et al. (2005) Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 109: 449-455
41. Nuttall JJC et al. (2004) Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: A case of immune reconstitution inflammatory syndrome. Pediatr Infect Dis J 23: 683-685
42. Kastrup O et al. (2005) Evolution of purely infratentorial PML under HAART - negative outcome under rapid immune reconstitution. Clin Neurol Neurosurg 107: 509-513
43. Kotecha N et al. (1998) Enhancing progressive multifocal leukoencephalopathy: An indicator of improved immune status? Am J Med 105: 541-543
44. Collazos J et al. (1999) Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS 13: 1426-1428
45. Miralles P et al. (2001) Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 15: 1900-1902
46. Hoffmann C et al. (2003) Progressive multifocal leukoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 74: 1142-1144
47. Tulius M et al. (2005) Inflammatory progressive multifocal leukoencephalopathy after antiretroviral treatment. AIDS 20: 469-471
48. Du Pasquier RA and Koralnik IJ (2003) Inflammatory reaction in progressive multifocal leukoencephalopathy: Harmful or beneficial? J Neurovirol 9 (Suppl 1): S25-S31
49. Jabs DA et al. (2002) Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 133: 48-61
50. Jacobson MA et al. (1997) Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 349: 1443-1445
51. Zegans ME et al. (1998) Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 125: 292-300
52. Karavellas MP et al. (2001) Immune recovery vitritis and uveitis in AIDS: Clinical predictors, sequelae, and treatment outcomes. Retina 21: 1-9
53. Goldberg DE et al. (2005) HIV-associated retinopathy in the HAART era. Retina 25: 633-649
54. Karavellas MP et al. (1998) Immune recovery vitritis associated with inactive CMV retinitis: A new syndrome. Arch Ophthalmol 116: 169-175
55. Karavellas MP et al. (1999) Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 179: 697-700
56. Song M-K et al. (2003) Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol 136: 696-702
57. Henderson HWA and Mitchell SM (1999) Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol 83: 540-545
58. + lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol 108: 17-23
59. Langford TD et al. (2002) Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 16: 1019-1029
60. Shelburne SA and Hamill RJ (2003) The immune reconstitution inflammatory syndrome. AIDS Rev 5: 67-79
61. Lipman M and Breen R (2006) Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis 19: 20-25
62. McComsey GA et al. (2001) Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 16: 321-327